Recruiting

NCT Number: NCT03400345

Human Upper Extremity Allotransplantation: F/U Protocol

Upper extremity allotransplantation is a new procedure which is becoming more common in the United States. Ongoing data collection for research purposes is vital to the long-term assessment as to the safety of the procedure and accompanying immunosuppression protocol, as well as quantifying patient outcomes and changes in quality of life. For these reasons, The Johns Hopkins Hand/Arm Transplantation Team is interested in enrolling transplanted patients in a follow-up protocol to continue collecting informative data to further the field of vascularized composite allotransplantation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Amputation, Traumatic Hand Injuries Wounds and Injuries Wounds and Injury

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Johns Hopkins University School of Medicine

Baltimore, Maryland, 21287, United States

Location status: Recruiting

Location contact

Carisa M Cooney, MPH, CCRP

CONTACT

[email protected]

443-287-4629

Damon S Cooney, MD, PhD

SUB_INVESTIGATOR

Jaimie Shores, MD

PRINCIPAL_INVESTIGATOR

Richard J Redett, MD

SUB_INVESTIGATOR

TBD TBD

CONTACT

443-287-7848

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Males and females 5 or more years post-unilateral or bilateral upper limb transplantation.
Completes the protocol informed consent form.
Consents to sample collection and storage (biopsies).
USA citizen or equivalent.
Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime.

Exclusion criteria

Candidate has not received an upper extremity allotransplant.
Any reason the study team thinks would cause the participant to be noncompliant or would put the patient at unacceptable risk if enrolled.

Treatment and study plan

Primary outcomes

Quality of life (QOL) for upper extremity transplant recipients via Functional Assessment with rehabilitation using Carroll Test

Time frame: Change from baseline QOL at end of study (approximately 5 years post-enrollment (±90 days))

Measures Grasp, Grip and Pinch Strength, Range of motion - Active & Passive. During rehabilitation sessions in clinic using activities resembling everyday tasks such as pouring water, opening/closing zippers and buttons, lifting blocks of different weight. Carroll test contains 33 questions and is scored from 0-3, 0- can perform no part of test, 1- performs test partially, 2-completes test, but takes abnormally long time or has great difficulty, and 3- performs tests normally.
QOL assessed for Hand Function by Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire

Time frame: Change from baseline QOL at end of study (approximately 5 years post-enrollment (±90 days))

The DASH Outcome Measure is scored in two components: the disability/symptom section (30 items, scored 1-5) and the optional high performance Sport/Music or Work section (4 items, scored 1-5). 1 indicating no difficulty and 5 indicating unable perform the function.
QOL assessed by Lawton Instrumental Activities of Daily Living (ADL/IADL) Questionnaire

Time frame: Change from baseline QOL at end of study (approximately 5 years post-enrollment (±90 days))

Questionnaire to asses Physical and instrumental activities for daily living. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). The scale will vary along a range of levels of competence- without any help, with some help, or does he need someone for the activities.
Michigan Hand Outcomes Questionnaire

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

Monitor function, pain, work performance, and aesthetics of hand(s). Responses from 1-5, 1 being very good and 5 being very poor
Short Musculoskeletal Function Assessment (SMFA)

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

The SMFA consists of two sections: 34 questions covering the assessment of the patients function and 12 questions covering how bothered patients are by their symptoms. Each question is scored 1 for no problems/no difficulty/not bothered (depending on the question) to 5 for unable to do a task/symptoms all the time/being greatly bothered.
Brief Pain Inventory (Short Form) (BPISF)

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

BPISF assesses the severity of pain and its impact on functioning. It is scored from 0 to 10, 0 indicating no pain, does not interfere to 10 indicating pain as bad as you can imagine, completely interferes.
Quality of life assessed for Psychological Measures by Brief Symptom Inventory

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

Brief Symptom Inventory questionnaire evaluates psychological distress and psychiatric disorders. It consists of 53-item self-report inventory in which participants rate the extent to which they have been bothered. 5-point rating scale, 0 indicating not at all bothered to 4 extremely bothered.
Psychological Measures by Satisfaction with Life Scale (SWLS)

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

SWLS is a measure of life satisfaction. Uses scale to rate from 1-7, Where 1 indicates Strongly disagree to 7 indicating strongly agree.
Psychological Measures assessed by Affect Balance Scale (ABS)

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

ABS is a 10-item questionnaire that assess positive and negative affect as indicators of life satisfaction and/or well-being. Score range from 0-4. 0 indicating the feeling never affected to 4, where the feeling is affected always.
Psychological Measures assessed by NEO Five-Factor Inventory (NEO-FFI)

Time frame: Change from baseline to end of study (approximately 5 years post-enrollment (±90 days))

NEO-FFI is used to examine personality traits. Questions consists of 60 items. Items are scored from Strongly disagree to Strongly agreed

Secondary outcomes

The efficacy of various immunosuppression regimens via ImmuKnow Assay/Cylex including immunomodulatory protocols (aka - Pittsburgh Protocol, Starzl Protocol), for maintenance of unilateral and bilateral upper extremity allotransplants.

Time frame: Annually for 5 years post-enrollment (±90 days)

For immune monitoring, to test cell mediated immunity. Value of ≤ 225 ng/mL indicates Low immune cell response, 226-524 ng/mL- Moderate Immune response, ≥525 ng/mL- High Immune cell Response.
Immunology- antibody testing by obtaining donor specific antibodies (DSA) by Luminex

Time frame: Annually for 5 years (±90 days)

For immune monitoring, to screen for donor specific antibodies.
Perform Skin Biopsy

Time frame: Annually for 5 years (±90 days)

To diagnose and assess acute rejection, Graft versus Host Disease and for surveillance of chronic rejection
Use CT Angiography

Time frame: Annually for 5 years (±90 days)

To delineate the outline and architecture of vasculature and blood flow patterns in the limb.
Magnetic Resonance (MR) Neurography

Time frame: Annually for 5 years (±90 days)

To help assess progression of nerve regeneration distal to the site of transplanted nerve coaptation.

Study contacts

Contact information is provided by the study sponsor or research team.

Jane Littleton, C.R.N.P

CONTACT

[email protected]

410-955-6875

TBD TBD

CONTACT

443-287-7848

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Registry information

Official study title

Human Upper Extremity Allotransplantation: Transplanted Patient Follow-Up Protocol

Important dates

Study start: 2017
Primary completion: 2036
Study completion: 2036
First posted: Jan 17, 2018
Registry last updated: May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting